These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 15564797

  • 1. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
    Yen WC, Prudente RY, Lamph WW.
    Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
    [Abstract] [Full Text] [Related]

  • 2. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP.
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [Abstract] [Full Text] [Related]

  • 3. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
    Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW.
    Cancer Res; 1998 Feb 01; 58(3):479-84. PubMed ID: 9458093
    [Abstract] [Full Text] [Related]

  • 4. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
    Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8656-64. PubMed ID: 15623650
    [Abstract] [Full Text] [Related]

  • 5. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
    Agarwal VR, Bischoff ED, Hermann T, Lamph WW.
    Cancer Res; 2000 Nov 01; 60(21):6033-8. PubMed ID: 11085524
    [Abstract] [Full Text] [Related]

  • 6. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.
    Bischoff ED, Heyman RA, Lamph WW.
    J Natl Cancer Inst; 1999 Dec 15; 91(24):2118. PubMed ID: 10601384
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
    Gamage SD, Bischoff ED, Burroughs KD, Lamph WW, Gottardis MM, Walker CL, Fuchs-Young R.
    J Pharmacol Exp Ther; 2000 Nov 15; 295(2):677-81. PubMed ID: 11046105
    [Abstract] [Full Text] [Related]

  • 8. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
    Yen WC, Lamph WW.
    Prostate; 2006 Feb 15; 66(3):305-16. PubMed ID: 16245282
    [Abstract] [Full Text] [Related]

  • 9. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
    Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA.
    Cancer Res; 1996 Dec 15; 56(24):5566-70. PubMed ID: 8971154
    [Abstract] [Full Text] [Related]

  • 10. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
    Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ.
    Cancer Prev Res (Phila); 2009 Feb 15; 2(2):161-7. PubMed ID: 19196723
    [Abstract] [Full Text] [Related]

  • 11. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
    Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.
    Cancer Epidemiol Biomarkers Prev; 2002 May 15; 11(5):467-74. PubMed ID: 12010861
    [Abstract] [Full Text] [Related]

  • 12. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr 15; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 13. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR, Dragnev KH.
    Oncologist; 2005 Jan 15; 10(1):22-33. PubMed ID: 15632250
    [Abstract] [Full Text] [Related]

  • 14. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.
    Cohen LA, Pittman B, Wang CX, Aliaga C, Yu L, Moyer JD.
    Cancer Res; 2001 Dec 15; 61(24):8683-8. PubMed ID: 11751385
    [Abstract] [Full Text] [Related]

  • 15. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
    Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH.
    Cancer Res; 2005 Apr 15; 65(8):3462-9. PubMed ID: 15833882
    [Abstract] [Full Text] [Related]

  • 16. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.
    Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH.
    Cancer Res; 2006 Dec 15; 66(24):12009-18. PubMed ID: 17178900
    [Abstract] [Full Text] [Related]

  • 17. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Rodon J, Jacobs CD, Chu Q, Rowinsky EK, Lopez-Anaya A, Takimoto CH, Wakelee HA.
    Cancer Chemother Pharmacol; 2012 Mar 15; 69(3):825-34. PubMed ID: 22057853
    [Abstract] [Full Text] [Related]

  • 18. Bexarotene induces cellular senescence in MMTV-Neu mouse model of mammary carcinogenesis.
    Shilkaitis A, Bratescu L, Green A, Yamada T, Christov K.
    Cancer Prev Res (Phila); 2013 Apr 15; 6(4):299-308. PubMed ID: 23430755
    [Abstract] [Full Text] [Related]

  • 19. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
    Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, Kline K.
    Exp Biol Med (Maywood); 2009 Oct 15; 234(10):1244-52. PubMed ID: 19657067
    [Abstract] [Full Text] [Related]

  • 20. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I.
    Jpn J Clin Oncol; 2000 Oct 15; 30(10):446-9. PubMed ID: 11185891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.